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Duchenne muscular dystrophy (DMD) is an X-linked recessive dis-
order characterized by progressive muscle degeneration and
weakness due to mutations in the dystrophin gene. The symptoms
of DMD share similarities with those of accelerated aging. Re-
cently, hydrogen sulfide (H2S) supplementation has been sug-
gested to modulate the effects of age-related decline in muscle
function, and metabolic H2S deficiencies have been implicated in
affecting muscle mass in conditions such as phenylketonuria. We
therefore evaluated the use of sodium GYY4137 (NaGYY), a
H2S-releasing molecule, as a possible approach for DMD treat-
ment. Using the dys-1(eg33) Caenorhabditis elegans DMD model,
we found that NaGYY treatment (100 μM) improved movement,
strength, gait, and muscle mitochondrial structure, similar to the
gold-standard therapeutic treatment, prednisone (370 μM). The
health improvements of either treatment required the action of
the kinase JNK-1, the transcription factor SKN-1, and the NAD-
dependent deacetylase SIR-2.1. The transcription factor DAF-16
was required for the health benefits of NaGYY treatment, but
not prednisone treatment. AP39 (100 pM), a mitochondria-targeted
H2S compound, also improved movement and strength in the dys-
1(eg33) model, further implying that these improvements are
mitochondria-based. Additionally, we found a decline in total sul-
fide and H2S-producing enzymes in dystrophin/utrophin knockout
mice. Overall, our results suggest that H2S deficit may contribute
to DMD pathology, and rectifying/overcoming the deficit with H2S
delivery compounds has potential as a therapeutic approach to
DMD treatment.
C. elegans | muscle | mitochondria | hydrogen sulfide | mouse
Duchenne muscular dystrophy (DMD) is an X-linked neu-romuscular disorder characterized by progressive muscle
degeneration and weakness (1). It is caused by mutations in the
gene that encodes for dystrophin, resulting in a decrease of func-
tional dystrophin protein in muscle cells and neurons. Dystrophin
links the intracellular cytoskeletal network to the transmembrane
components of the dystrophin–glycoprotein complex, which pro-
vides stability to the muscle membrane. Destabilization of this
complex from the reduction of dystrophin results in progressive
muscle-fiber damage and membrane leakage (2). In addition, re-
duction of dystrophin causes increased sarcoplasmic calcium lev-
els, which may cause a cascade of detrimental effects, including
mitochondrial damage (3–7). DMD is a disorder that affects over
1 in 3,500 live male births. Prognosis is very poor, and currently
there is no cure. Treatments are largely targeted at controlling
the symptoms and focus on maximizing quality of life. Although
the current standard pharmaceutical treatment, the corticoste-
roid prednisone, extends the ambulatory period by a couple of
years, prednisone treatment is associated with several undesir-
able side effects, such as weight gain and behavioral difficulties,
and may lead to osteoporosis (8). There has been an increased
interest in exon-skipping therapies to make the condition resemble
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the less severe form Becker muscular dystrophy (9). Two anti-
sense oligonucleotide-based therapies have received accelerated
approval from the Food and Drug Administration, and two others
are in clinical trials (10–12). However, this is still not a cure. Thus,
there remains an unmet clinical need in seeking new and/or al-
ternative treatments for DMD that can be used independently or
in conjunction with other emerging therapies (13).
While the repurposing of medications approved for other uses
in patients is a possibility, drug discovery often first utilizes an-
imal and in vitro models to assess potential efficacy. DMD has
been studied in mouse and canine models, as well as the inver-
tebrate model Caenorhabditis elegans [reviewed by McGreevy
et al. (14)]. C. elegans have a short lifespan, a low maintenance
cost, a fully sequenced genome, and biological pathways con-
served with humans (15). Due to its largely conserved muscula-
ture and neuromuscular junction, C. elegans has proven itself as a
useful model for studying human muscle disorders, such as mus-
cular dystrophy and sarcopenia (16–18). The DMD worm model
has been employed for studying the use of pharmacological treat-
ments and in a large-scale drug screen (19). Several models have
been established for studying DMD by introducing mutations in
dys-1 (the dystrophin ortholog), which results in a loss of fully
functional dystrophin. Here, we utilized C. elegans with a nonsense
mutation at position 3,287 of the DYS-1 dystrophin ortholog (20).
These dys-1(eg33) worms displayed impaired locomotion, reduced
strength, elevated calcium levels, disrupted mitochondrial structure,
and increased use of oxygen (5, 20–22). Importantly, the clinically
used DMD drug prednisone has been shown to improve move-
ment, strength, and mitochondrial structure in this model, con-
firming the utility of dys-1(eg33) worms as a DMD drug-screening
platform (19, 22).
Fig. 1. Effect of NaGYY on movement, strength and gait in dys-1(eg33). (A) dys-1(eg33) had a lower thrash rate than WT. NaGYY treatment significantly
improved the thrash rate of dys-1(eg33) in a dose-dependent manner (10 μM to 1 mM). The NaGYY hydrolysis compound (100 μM), which was unable to
generate H2S, was also assessed and showed no difference in thrash rate compared to dys-1(eg33), demonstrating that it is H2S from NaGYY, and not the
parent molecule or hydrolysis product formed after H2S generation, that was providing the beneficial effect. For all strains and treatments, n = 10 with five
replicates with three biological repeats for a total of 150 data points per violin. Results were analyzed with a two-way ANOVA. All significance points are
compared to dys-1(eg33). *P < 0.05; ***P < 0.0001; ns, P > 0.05. (B) The dys-1 mutant had reduced strength compared to WT animals. NaGYY(100 μM)
improved the strength of dys-1(eg33) animals beyond WT levels. For all strains and treatment groups, n = 21 to 33. Results were analyzed with a one-way
ANOVA. All significance points are compared to dys-1(eg33). ***P < 0.0001. (C) Activity parameters that decline with age also declined in the DMD worm
model. NaGYY (100 μM) improved wave-initiation rate, brush stroke, and activity index, but not travel speed. (D) Morphological parameters which increase
with age were also increased in the DMD model, with the exception of curling (no significant difference with respect to WT animals). NaGYY (100 μM)
improved body-wave number and stretch, but did not improve asymmetry or curling. For all strains and treatments, n = 74 to 79. Results were analyzed by
using a Kruskal–Wallis test. All significance points were compared to dys-1(eg33). *P < 0.05; **P < 0.01; ***P < 0.0001. ns, P > 0.05. Results are presented as a
violin plot to show the frequency distribution of the data; the solid line represents the median, and the quartiles are represented by the dotted lines.
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DMD and aging share some similarities, primarily the pro-
gressive loss of skeletal muscle mass (23). DMD is characterized
by rapidly progressive muscle degeneration, and aging is usually
associated with sarcopenia. C. elegans display a stereotypical
histopathological progression of muscle decline both in DMD
(24) and with age (25). In both cases, loss of mitochondrial struc-
ture is an early feature. Alterations in mitochondrial gene expres-
sion are known to occur prior to onset of symptoms in DMD C.
elegans (26), and this impairment of mitochondrial function causes
sarcomere disorganization (27). It has recently been shown that hy-
drogen sulfide (H2S), improved both survival and health of aging C.
elegans by attenuating intracellular reactive oxygen species (ROS)
generation and protecting against various stressors (28, 29).
H2S is a signaling “gasotransmitter” that is produced endog-
enously in mammals and in C. elegans. It is generated through
the activity of three enzymes: cystathionine-γ-lyase (CSE), cys-
tathionine-β-synthase (CBS), and 3-mercaptopyruavate transferase
(3-MST). Endogenous H2S has been shown to have cytopro-
tective and antiapoptotic effects that may help to regulate vari-
ous functions within the human body (28–30). In recent years,
the use of H2S supplementation has been gaining attention due
to its potential use in aging and age-associated diseases. H2S
supplementation has been shown to slow the aging process by
inhibiting oxidative stress and free-radical reactions [reviewed by
Zhang et al. (30)]. Further to this, metabolic H2S deficiencies
have been implicated in conditions such as phenylketonuria,
which also affects muscle mass, highlighting the potential use
of H2S supplementation in muscle-related disorders (31). We
therefore hypothesized that H2S supplementation, using a slow-
release H2S donor [sodium GYY4137 (NaGYY) (32)] and a
Fig. 2. H2S ameliorated fragmentation of the mitochondrial network and delayed cell death, but did not improve defects in mitochondrial membrane
potential or improve overall lifespan. (A) Representative images of CB5600 (WT with GFP-tagged mitochondria), which displayed a tubular mitochondrial
network. CC91 [dys-1(eg33) with GFP-tagged mitochondria], which showed severe fragmentation of the mitochondrial network. NaGYY (100 μM)-treated
CC91 animals displayed a normal mitochondrial network similar to that of WT. For all strains and treatments, n = 20. (B) JC-10 stained mitochondria in WT
animals, and dys-1(eg33) showed a severely depolarized mitochondrial membrane, which is not improved by NaGYY (100 μM) treatment. For all strains and
treatments, n = 20. (C) Lifespan curves were obtained by using the NemaLife. dys-1(eg33) has a shorter median lifespan (9 d) than WT (11 d), but NaGYY (100
μM) did not appear to extend lifespan in dys-1(eg33) animals (10 d). For all strains and treatments, n = 274 to 315, from two biologically independent repeats.
Results were analyzed by using Kaplan–Meier curves, with Bonferroni-corrected multiple comparisons. ***P < 0.01. ns, P > 0.05. (D) Representative images of
muscle-cell death in CB5600, CC91, and CC91 treated with NaGYY (100 μM). Muscle-cell death (as identified by the absence of muscle nuclei) increased with
age in all animals, but was more severe in the dys-1(eg33) animals. NaGYY (100 μM) treatment appeared to slow the onset in cell death in dys-1 animals. Vulva
is identified by the *, and arrows show the missing nuclei. For all strains and treatments, n = 30. (Scale bar: 30 μm.)
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mitochondria-targeted H2S delivery molecule [AP39 (33, 34)],
would also give some beneficial effects in the C. elegans dys-
1(eg33) model (22).
Here, we report that NaGYY improved DMD worm move-
ment, strength, gait, and muscle mitochondrial structure. Similar
to prednisone treatment, NaGYY treatment did not improve
mitochondrial membrane potential. NaGYY also delayed mus-
cle cell death, but did not significantly alter overall lifespan. The
health improvements of both prednisone and NaGYY treatment
required the action of the kinase JNK-1, the transcription factor
SKN-1, and the NAD-dependent deacetylase SIR-2.1. The tran-
scription factor DAF-16 was required for the health benefits of
NaGYY treatment, but not prednisone treatment. Despite at
least partially nonoverlapping mechanisms of action, combined
treatment of DMD worms with both NaGYY and prednisone
did not improve health more than either compound alone. The
improvements seen are likely due to improving mitochondrial
health, as NaGYY did not restore the normal calcium fluxes
expected if dystrophin was restored and as confirmed using AP39
[the mitochondria-targeted H2S delivery molecule (33, 34)]. We
also found a decline in total sulfide and in H2S-producing en-
zymes in a DMD rodent model, which suggests that there is a
therapeutic utility with these compounds to overcome H2S de-
ficiency in DMD skeletal muscle by targeting key intracellular
components such as the mitochondria. Our results demonstrate
the positive effects of H2S supplementation on DMD nematode
health and open avenues of both therapeutic and mechanistic
inquiry.
Results
NaGYY Treatment Improved C. elegans DMD Functional Defects in
Movement, Strength, and Gait. As is the case with DMD pa-
tients, worms with a mutation in dystrophin exhibit decreased
movement (22). In worms, this can be assessed by measuring the
worm’s thrash rate in a liquid medium (35). For all experiments,
unless otherwise stated, L1 worms were synchronized to plates
with or without compound and left to grow at 20 °C until day 1 of
adulthood, when they could then be used. As shown in Fig. 1A,
the decreased movement of dys-1(eg33) worms was attenuated by
treatment with the slow-release H2S-generating molecule NaGYY.
This improved movement was observed in a dose-dependent
manner from 10 μM to 1 mM (Fig. 1A); 100 μM was subse-
quently used throughout this study unless otherwise stated. Control
experiments performed by using hydrolyzed compound [synthesized
as described in Alexander et al. (32)] incapable of generating H2S
confirmed that the effects observed were due to H2S and not either
the parent compound or hydrolysis product (Fig. 1A).
Recently, it has been shown that, as with DMD patients, dys-
1(eg33) worms display muscle weakness (22). This report was en-
abled by a novel device called the NemaFlex (36), which has also
been used to demonstrate muscle weakness in a worm-limb-girdle
muscular dystrophy model (37). As shown in Fig. 1B, treatment
with NaGYY also attenuated the strength loss observed in dys-
1(eg33) worms.
Both DMD patients and dys-1(eg33) worms are known to
display an altered gait, with patients displaying a waddling gait
and worms displaying alterations in head and body bending
(38–40). Recently, the C. elegans Swim Test (CeleST) has been
developed as an objective method for assessing worm gait (41).
CeleST reports eight different parameters, four of which are
activity related, and the other four of which are morphological
features. Activity-related parameters in dys-1(eg33) worms are
shown in Fig. 1C; these include wave initiation rate, travel speed,
brush stroke, and activity index (Fig. 1C). These activity-related
parameters have been found to decline with age (41), and dys-
1(eg33) also displays a decline in all these parameters compared
with wild-type (WT). Aside from travel speed, all parameters
were improved with NaGYY supplementation (Fig. 1C). Body
wave number, asymmetry, curling, and stretch (Fig. 1D) are all
morphological parameters that have been shown to increase with
age (41). These four measures, apart from curling, are also in-
creased in dys-1(eg33) compared to WT. NaGYY treatment re-
duced the number of body waves and improved stretch, but did
not impact curling or asymmetry (Fig. 1D). These results sug-
gested that DMD worms display gait abnormalities as seen in
older worms and that NaGYY treatment improved most activity
parameters, but largely did not improve the morphological fea-
tures of the DMD worms’ altered gait.
NaGYY Improved Mitochondrial Structure in dys-1(eg33) Worms.
Prednisone treatment has been shown to improve DMD worm
movement and strength, and this was linked to improvements in
mitochondrial structure (22). We therefore tested whether the
beneficial effects induced by NaGYY shown in Fig. 1 were due
to improved mitochondrial structure. As shown in Fig. 2A, dys-
1(eg33) animals had a severely fragmented mitochondrial net-
work that was improved by treatment with NaGYY. We there-
fore next examined the effects of NaGYY on mitochondrial
membrane potential (ΔΨm) using the potentiometric fluorophore
JC-10, which accumulates inside the mitochondrial membrane
and exits the mitochondria based on mitochondrial membrane
potential (35). Previously, prednisone had been shown to not
significantly improve ΔΨm (22). This is also the case here, where
NaGYY failed to improve ΔΨm, suggesting that H2S-mediated
improvement of DMD worm health proceeds through similar
mechanisms (i.e., mitochondrial structural improvement) as the
clinically used drug prednisone (Fig. 2B). We then assessed
overall lifespan of these animals and found that dys-1(eg33)
(median 9 d, mean 9.5 d, and maximum 22 d) had a significantly
reduced lifespan compared to WT (median 11 d, mean 11.5, and
maximum 24 d). NaGYY did not significantly improve the life-
span of the dys-1(eg33) animals (median 10 d, mean 9.8 d, and
maximum 21 d) (Fig. 2C). We also assessed muscle-cell death in
these mutants with NaGYY treatment, as age-dependent muscle-
cell death has been shown to be accelerated in dys-1 mutants (20),
and this acceleration was reduced with prednisone treatment (19).
We found that NaGYY was able to delay muscle-cell death, sug-
gesting an improvement in healthspan, but not in lifespan (Fig. 2D).
NaGYY-Improved Movement Response Required the Same Genes in
both Older Worms and DMD Worms. The mechanisms by which
NaGYY treatment extended lifespan and improved healthspan
in aging animals had been assessed previously by examining
changes in gene expression in response to treatment (28, 29).
Therefore, to determine if the mechanisms by which H2S im-
proved health in DMD worms were largely the same as those in
aging worms, we assessed the same genes in DMD worms. As
shown in Fig. 3A, jnk-1, skn-1, daf-16, and sir-2.1 were all re-
quired for the full beneficial effect of NaGYY treatment in
DMD worms. While there was a small effect of NaGYY treat-
ment in DMD worms with sir-2.1 knocked down by RNA in-
terference (RNAi), sir-2.1 was clearly required for the full
improved movement (Fig. 3A). These results suggested that the
mechanisms by which NaGYY treatment improved health with
age are likely the same mechanisms which improved health in
DMD worms.
Improved Movement in Response to Prednisone Treatment Did Not
Require daf-16. The molecular mechanism(s) responsible for
prednisone’s clinical efficacy in DMD is still under investigation,
but at least part of the mechanism is likely due to it its anti-
inflammatory effects. The binding of prednisone (and other glu-
cocorticoids) to the glucocorticoid receptor triggers the inhibition
of the transcription factor nuclear factor kappa-light-chain-en-
hancer of activated B cells, which is responsible for causing in-
flammation [reviewed by Herbelet et al. (42)]. Although C. elegans
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lack an inflammatory system and satellite cells (16), prednisone
is still able to improve DMD worm health. We therefore wanted
to determine whether the mechanism(s) by which NaGYY
treatment improved DMD health were similar to prednisone. As
shown in Fig. 3B, jnk-1, skn-1, and sir-2.1 are all required for the
full beneficial effect of prednisone treatment on DMD worms.
The set of genes required for the full beneficial effect of pred-
nisone treatment is therefore similar to the results observed with
NaGYY treatment on DMD worms (Fig. 3A). However, in
contrast to treatment with NaGYY, prednisone did not appear
to require daf-16 for most of its beneficial effects. In the absence
of daf-16, prednisone still resulted in a 30% increase in move-
ment, compared to a 40% increase with daf-16 present; this
difference is not statistically significant (Fig. 3B).
These results suggest that the mechanisms by which NaGYY
and prednisone treatment improve health in DMD worms are
broadly similar, but that insulin signaling does not appear to be a
major component of the mechanisms by which prednisone im-
proves health in DMD worms.
Combined NaGYY and Prednisone Treatment Does Not Provide
Additional Health Improvement in DMD Worms. There is increased
evidence to suggest that future treatments in DMD will include
combined therapies in order to optimize treatment efficacy (43).
As NaGYY and prednisone appeared to have similar beneficial
effects acting via at least partially distinct mechanisms, we next
investigated whether utilizing a combined treatment of predni-
sone and NaGYY would provide a greater improvement in DMD
Fig. 3. The mechanism of action of prednisone and NaGYY: The effect of RNAi treatment on aging- and stress-related genes and combined treatments. (A)
NaGYY(100 μM) required the presence of jnk-1, skn-1, daf-16, and sir-2.1 to improve movement in the dys-1(eg33) model. (B) Prednisone (370 μM) also re-
quired the presence of jnk-1, skn-1, and sir-2.1 for its beneficial effect, but was able to largely restore movement in the absence of daf-16. (C) Combination
therapy of prednisone and NaGYY did not provide increased beneficial effect. For all strains and conditions, n = 10 with five replicates and three biological
independent repeats, equating to 150 points per bar. Results were analyzed with a two-way ANOVA. ***P < 0.001; ns, P > 0.05 [statistical significance
compared to dys-1(eg33)]. †P < 0.0001 (statistical significance compared to prednisone). ‡P < 0.0001 (statistical significance compared to NaGYY). Results are
presented as a violin plot to show the frequency distribution of the data; the solid line represents the median, and the quartiles are represented by the
dotted lines.
Fig. 4. Acute treatment with NaGYY initially increased the movement capacity of dys-1(eg33) animals and delayed the age-related movement decline. (A)
NaGYY (100 μM) improved movement both chronically and acutely. It initially increased the movement capacity of the animals, as shown after 24 h of ex-
posure, and then it delayed the decline through the 48-h exposure. (B) NaGYY (100 μM) treatment given at day 6 of adulthood (postreproduction) still gave a
beneficial effect 24 h after exposure. There was no improvement on day 7 adults after 24 h of treatment. (C) The effects of NaGYY (100 μM) was observed
after 1-h exposure in day 1 adults. For all strains and conditions, n = 10 with five replicates and three biological independent repeats, equating to 150 points
per bar. Results were analyzed with a two-way ANOVA. All significance points are compared to dys-1(eg33). ***P < 0.001. ns, P > 0.05. Results are presented
as a violin plot to show the frequency distribution of the data; the solid line represents the median, and the quartiles are represented by the dotted lines.
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worm movement than the treatments being given independently.
As shown in Fig. 3C, when 370 μM prednisone and 100 μM
NaGYY were given in combination, DMD worms experienced a
decrement in movement. This result suggested an interaction
between prednisone and NaGYY, perhaps due to overlapping
mechanism(s) of action. To confirm that the interaction was
reflective of the doses used in each treatment, we examined the
dose dependence of the interaction. As shown in Fig. 3C, when
either prednisone or NaGYY was used to treat DMD worms at
the optimal dose (370 μM and 100 μM, respectively), and the
other treatment was given in combination at lower doses, DMD
worm movement improved, though not to the level when either
compound was given independently. These results suggested that
the interaction between the treatments was dose-dependent.
NaGYY Given Postdevelopmentally Rapidly Improved Health. Clini-
cally, DMD patients are usually diagnosed before age 5, where
diagnosis is defined by the onset of associated symptoms (44).
Therefore, any potential treatment should have a beneficial ef-
fect during childhood and ideally during adulthood as well.
Previously, chronic treatment with H2S has been shown to
modulate the effects of age-related declines in muscle function,
yet insulin-like signaling has been shown to act in adulthood to
regulate C. elegans lifespan (45). Thus, we investigated whether
NaGYY supplementation in adulthood could improve move-
ment in adult DMD worms. As shown in Fig. 4A, DMD worms
displayed a progressive decline in movement, as reported pre-
viously in aging WT worms (25). DMD worms were then grown
to adulthood on noncompound plates. On day 1 of adulthood,
worms were transferred to NaGYY plates to see if acute treat-
ment would be useful. Acute treatment with NaGYY on day 1 of
adulthood improved movement for at least the next 2 d (Fig. 4A).
Acutely treating DMD worms with NaGYY can yield improved
movement in animals as old as day 6 adults, as these animals
exhibited higher movement 24 h after treatment. Day 7 adults
treated with NaGYY for 24 h did not show an improved move-
ment, suggesting this is the threshold at which no amelioration is
observed (Fig. 4B). These results confirm that improved DMD
worm health from NaGYY treatment can be achieved into the
postreproductive stage for worms. As acute NaGYY treatment in
adults gave an improved movement, we were curious as to how
quickly movement could be improved in response to NaGYY
treatment. As shown in Fig. 4C, movement improved within 1 h of
treatment with NaGYY for day 1 adults (Fig. 4C), indicating the
ability of NaGYY to rapidly improve animal movement.
The Health Benefits of H2S Supplementation Appeared to Be Largely
Mitochondria-Mediated. A well-known underlying mechanism of
DMD is loss of calcium homeostasis (3). We therefore assessed
whether NaGYY was improving calcium handling. We used the
NemaMetrix ScreenChip system to take electropharyngeogram
(EPG) recordings of stimulated pumping, where each contrac-
tion is associated with an action potential (46). The traces for the
dys-1(eg33) animals were significantly different from WT. They
had a reduced frequency in pumping, an increase in pump du-
ration, and an increased interpump interval (Fig. 5A). NaGYY
treatment significantly improved these measures, but, like move-
ment, not to WT levels. This observation suggested that, as with
prednisone, restoration of dystrophin at the sarcolemma was un-
likely the primary mechanism of action of NaGYY.
Given that dys-1(eg33) animals display reduced spare respi-
ratory capacity (22), we hypothesized that they would be hy-
persensitive to mitochondrial electron-transport chain inhibition.
The inhibitor antimycin A has been shown to cause paralysis and
muscle-cell damage in WT animals due to the mitochondrial
dysfunction (27). As shown in Fig. 5B, dys-1(eg33) animals were
hypersensitive to treatment with antimycin A, and this hyper-
sensitivity was significantly reduced by treatment with NaGYY.
To demonstrate that H2S supplementation was reversing anti-
mycin A hypersensitivity by acting directly in the mitochondria,
we used the mitochondria-targeted H2S compound AP39 (33, 34).
AP39 (100 pM) also reversed antimycin A hypersensitivity (Fig. 5B),
confirming that specific intramitochondrial H2S supplementation was
sufficient to rescue mitochondrial dysfunction in the DMD animals.
We therefore confirmed that targeting H2S to the mitochondria
using AP39 was also sufficient for improved physiological parameters
of movement (dose–response in Fig. 5C) and strength (Fig. 5D).
Sulfide Levels and H2S-Producing Enzyme Levels Were Reduced in
Dystrophin/Utrophin Knockout Mice. Finding that H2S supplemen-
tation improved DMD worm health raised the question of whether
H2S levels, like NAD levels (47), were reduced across species in
DMD.We therefore performed a pilot study in two rodent models
of DMD alongside WT rodents (n = 6 per condition). We used
the traditional mdx mouse model, which does not show any ob-
vious clinical signs of the condition, and the more severe dystro-
phin and utrophin deficient double-knockout (dKO) mutant,
which shows a closer resemblance to human DMD pathology (48).
Consistent with past studies, we observed a decline in gastrocne-
mius muscle weight in the dKO animals, but not in the mdx mice
(Fig. 6A). Total sulfide levels were significantly increased in the mdx
animals and decreased in the dKO animals compared toWT (Fig. 6B).
This suggests that the mdx animals may have a compensatory mech-
anism that is overwhelmed in the dKO animals. Thus, we examined the
expression of the H2S-producing enzymes CSE and 3-MST. CSE is
predominantly cytosolic and translocates to the mitochondria with
stress, whereas 3-MST is mainly mitochondrial (49). Both enzymes
were significantly decreased in the dKO animals (Fig. 6 C and D).
Overall, these results imply that H2S metabolism is altered in DMD.
Discussion
Pharmacological H2S Improved Health in the C. elegans DMD Model.
H2S was previously considered a highly toxic gas. However, re-
cent evidence demonstrated that it is endogenously produced in
animals, which suggests that it may exhibit antiapoptotic, anti-
inflammatory, and cytoprotective effects (50). H2S supplemen-
tation has been demonstrated to modulate the lifespan and health-
span of C. elegans (28, 29). Due to similarities in loss of muscle
function with age and in DMD worms, we tested if H2S could
improve DMD health. We determined that H2S administered in
the form of the slow-release H2S donor NaGYY could improve
DMD worm movement, gait, and strength, as well as improve
muscle mitochondrial structure, all at a dose that was previously
reported to improve C. elegans healthspan (28, 29). NaGYY, like
prednisone (19), can delay muscle-cell death, but does not im-
prove lifespan (Fig. 2 C and D). Notably, NaGYY can be ad-
ministered postdevelopmentally and for several days postadulthood
to improve worm movement, suggesting that H2S supplementation
can be given acutely. A control compound has been used in this
study, which provides further evidence that it is likely the H2S
that has been supplemented that is having the therapeutic effect.
A limitation of this study is that we did not know the drug
concentration inside of the animal, only the dose that we ad-
ministered. However, the dose we used was the same as what has
been reported previously with commercial GYY4137 (28, 29).
AP39, the mitochondria-targeted H2S compound, was also able
to improve movement and strength in the dys-1(eg33)model. It is
also important to note that AP39 was given at a substantially
lower dose (100 pM) compared to NaGYY (100 μM) or pred-
nisone (370 μM), meaning that toxicity is less likely. Although it
is well known that DMD shows evidence of oxidative stress (51)
and H2S has been proposed as an antioxidant (30), it is unlikely
that the beneficial effects of NaGYY or AP39 were due to “oxi-
dant scavenging” or direct “antioxidant” activity. Firstly, the rate
constants of reaction of bolus sulfide with physiological oxidants
such as O2
•−, H2O2, ONOO− in vitro, even at concentrations several
6 of 12 | PNAS Ellwood et al.
https://doi.org/10.1073/pnas.2018342118 Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans






















orders of magnitude higher than we have used (e.g., 5 mM NaSH),
and in the absence of any competing biological milieu is far too slow
to be physiologically relevant (52). Secondly, H2S generated via
NaGYY (100 μM) (32) and AP39 (100 pM) (33, 34) is likely to slow,
and resulting H2S levels would be insufficient even after complete
hydrolysis to at least partially compensate for unfavorable reaction
kinetics, even in the absence of competing cellular substates.
Mechanisms Underlying Prednisone and NaGYY Treatment in Improved
DMD Worm Health. The primary cause of DMD is the loss of fully
functional dystrophin protein, which results in a loss of membrane
stability. In C. elegans, DYS-1 is required for the proper locali-
zation of several calcium channels (53–56). The mislocalization
of these channels disrupts calcium homeostasis, resulting in el-
evated cytosolic calcium (5), a condition known to impair mi-
tochondrial membrane potential [reviewed by Contreras et al.
(57)]. Thus, the underlying loss of calcium homeostasis in DMD
worms (5, 27) does not appear to be corrected by either prednisone
or NaGYY treatment, since mitochondrial membrane potential is
not restored by either treatment in DMD worms. EPG traces
confirmed altered electrophysiologic function in DMD worms, and
NaGYY treatment did not fully restore normal electrophysiologic
Fig. 5. The physiological improvements from H2S supplementation were largely mitochondria-based. (A) EPG traces show a decline in pump frequency, an
increase in pump duration, and an increase in the inter pump interval in dys-1(eg33) animals. NaGYY (100 μM)-treated animals showed a partial improvement
in these parameters. For all strains and conditions, n = 15 with two independent biological repeats, equating to 30 data points per bar. Results were analyzed
by one-way ANOVA. All significance points are compared to dys-1(eg33). **P < 0.01; ***P < 0.001. (B) dys-1(eg33) animals were hypersensitive to antimycin A.
NaGYY (100 μM) and the mitochondria-targeted H2S AP39 (100 pM) ameliorated this hypersensitivity. (C) Dose–response curve of the thrash rate of dys-
1(eg33) at different AP39 concentrations. (D) As with NaGYY (100 μM), AP39 (100 pM) treatment improved movement and strength of dys-1(eg33)-treated
animals. For movement assay, all strains and conditions are n = 10 with five replicates and three biological independent repeats, equating to 150 points per
bar. Results were analyzed with a two-way ANOVA. All significance points are compared to dys-1(eg33). ***P < 0.001. For strength, n = 21 to 33. Results were
analyzed with a one-way ANOVA. All significance points are compared to dys-1(eg33). ***P < 0.0001. Results are presented as a violin plot to show the
frequency distribution of the data; the solid line represents the median, and the quartiles are represented by the dotted lines.
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function in DMD worms. Taken together, these results suggest
that calcium homeostasis is improved, but not to an extent that
allows for sustained improvements in mitochondrial membrane
potential. Therefore, the calcium channels at the plasma mem-
brane are likely still mislocalized, as DYS-1 levels are not re-
stored in response to treatment with NaGYY.
However, the improved structure of muscle mitochondria
(Fig. 2A) suggests that prednisone and NaGYY preserve mito-
chondrial integrity via an alternate mechanism. The ability of
NaGYY coupled with the ability of AP39, the mitochondria-
targeted H2S compound, to reverse electron-transport chain in-
hibition hypersensitivity, demonstrates that H2S is acting intra-
mitochondrial in DMD worms. Furthermore, the ability of AP39
to restore movement and strength in DMD worms highlights that
mitochondrial H2S supplementation is sufficient to improve DMD
worm health. This raises the interesting question of whether
prednisone and/or H2S supplementation is acting in a manner
similar to NAD supplementation, which has also been shown to
be beneficial in worm and rodent DMD muscle (47), or if they
are acting in other ways to improve mitochondrial function to
compensate for impaired membrane potential. The mitochon-
drial site of action likely explains the decreased cell death in
response to NaGYY treatment. Importantly, it has recently been
shown that while NAD supplementation does improve rodent
DMD muscle, it does not fix all elements of the pathology (58).
As H2S acts on mitochondria, we similarly do not anticipate that
H2S supplementation will fix all elements of the pathology, a
suggestion supported by the lack of lifespan improvement, despite
cell-death improvement.
In addition to potentially having direct effects upon the re-
spiratory chain (29, 59–61), prednisone and H2S could be im-
proving health via activation of stress and/or adaptation pathways.
Previously, jnk-1, skn-1, daf-16, and sir-2.1 were shown to be
required for the beneficial effects of H2S treatment on C. elegans
lifespan extension (28). jnk-1 is an ortholog of human MAPK, a
stress-activated protein kinase (62), and has been shown to be a
regulator of longevity and a mediator of the stress response (62,
63). Thus, as jnk-1 was required for the full beneficial effects of
both prednisone and NaGYY treatment, it appears that one
mechanism of action of both treatments is via improved stress
tolerance (Fig. 3 A and B).
skn-1 and daf-16 are both transcription factors and are
orthologs of human NFE2 and FOXO, respectively. NFE2 is a
regulator of oxidative stress and proteostasis (64), and FOXO is
a regulator of metabolic and stress-responsive pathway-encoding
genes [reviewed by Sun et al. (65)]. Thus, as skn-1 was required
for the full beneficial effects of both prednisone and NaGYY,
both treatments appear to induce nuclear-encoded gene expres-
sion, which may have accounted for the improved mitochondrial
structure observed in response to both treatments (Fig. 3 A and
B). Similarly, as daf-16 was required for the positive effects of
NaGYY, but not prednisone, treatment, altered expression of
metabolic genes may underlie part of the mechanisms of action
of NaGYY, but not prednisone, treatment. This observation is
interesting, given that prednisone can induce steroid diabetes
with prolonged use (66, 67).
Lastly, sir-2.1 is a human ortholog of sirtuin 1 (NAD-dependent
deacetylase), which is involved in many cellular processes, in-
cluding metabolism, stress, cellular senescence, and aging (68).
Thus, there is a common theme: Genes required for the full
therapeutic effects of prednisone and NaGYY are involved in
the regulation of the stress response and mitochondrial gene
expression. These observations seem consistent with the im-
proved mitochondrial structure and overall animal health and
suggest that DMD worms may be hypersensitive to any external
stressors, such as the recently reported hypersensitivity to
exercise (5).
Future Directions. Currently, there is no cure for DMD, and
treatment options are limited. The main approved treatment is
the use of glucocorticoid medications, with the most common
form prescribed being the corticosteroid prednisone. Although
the specific mechanism of prednisone is not fully known, long-
term daily treatment has been shown to improve muscle strength
and prolong independent ambulation from 6 mo to 2 y longer
than in those not receiving corticosteroid (8). As with all steroid
usage, there are often several undesirable side effects. In the
short term, these are likely to be weight gain and mood changes,
and in the long-term, side effects include growth suppression,
thinning of bones, and diabetes (8). Our results suggest that not
only should other compounds that have mitochondrial effects,
such as prednisone, be examined for efficacy in treating DMD,
but also that the combination therapy involving prednisone and
decreased insulin signaling, could be examined. Furthermore,
combination therapy with emerging exon-skipping and other
treatments should also be explored.
The finding that NaGYY treatment recapitulated the benefi-
cial effects of prednisone for DMD phenotypes in worms sug-
gests that not only could H2S be examined as a potential
treatment for DMD, but also for greater understanding of why
H2S has therapeutic value and what the role of H2S is in the
Fig. 6. DMD rodent models displayed “H2S deficiency”: Total sulfide levels
and expression of H2S enzymes were altered in DMD rodent models. (A)
There was a decline in muscle weight in the dKO (utrophin/dystrophin de-
ficient) mice compared to WT. (B) Total sulfide levels were increased in the
mdx mouse and decreased in the dKO animals. (C and D) Protein expression
of CSE and 3-MST were decreased in dKO animals, respectively. (C and D,
Upper) Representative blots represent individual animals in each lane. n = 6
per condition. Results were analyzed with a one-way ANOVA. *P < 0.05
(significance for mdx relative to WT); †P < 0.05 (significance for dKO relative
to WT). Results are presented as a violin plot to show the frequency distri-
bution of the data; the solid line represents the median, and the quartiles
are represented by the dotted lines.
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DMD pathology. AP39 treatment also improved movement and
strength, suggesting that mitochondrial H2S has therapeutic
value due to action in the mitochondria, such as improved cel-
lular bioenergetics and adenosine triphosphate (ATP) synthesis,
prevention of oxidant formation, preservation of mitochondrial
DNA integrity, and delaying onset of cell death and inflamma-
tion (69, 70). Given that enzymes involved in the synthesis of H2S
are known to translocate to the mitochondria in response to
stress, H2S could potentially be produced in DMD muscle in
order to compensate for mitochondrial stress. In particular, CBS
and CSE translocate to the mitochondria in response to hypoxia
to sustain ATP production (49). The 3-MST is found in both the
cytosol and the mitochondria, but predominantly in the mito-
chondria. If this is the result of mitochondrial H2S depletion,
then it is likely that the supplementation is acting to restore some
mitochondrial function, much like NAD supplementation has
been shown to do (47). The pilot data from DMD rodent models
suggest that H2S levels are increased in mdx mice, but they are
decreased in dKO mice. These data suggest that, H2S levels may
increase in response to mitochondrial stress. Similarly, the pilot
data from mdx and dKO mice suggest that H2S-producing en-
zymes may become depleted in response to increased mito-
chondrial stress, resulting in eventual failure of the H2S stress
response. Further work is required to determine if these sup-
positions are true and if H2S supplementation in rodents is able
to improve health. Similarly, if increased H2S improves mito-
chondrial function without altering membrane potential (as our
data suggest in Fig. 2 A and B), the question arises of whether
there are other treatments/mechanisms that could be similarly
explored.
It is interesting to note that in both the worm and mouse
models, animals are genetically identical [i.e., homozygous for
the same mutation(s)], yet have variable individual results. It is
unclear whether stochastic differences in global gene expression
or environmental differences underlie the variability. Notably,
both the response to H2S supplementation in worms and H2S-pro-
ducing enzymes in rodents is highly variable at the individual level.
This raises the interesting question of whether individual dif-
ferences in mitochondrial function/homeostasis underlie individ-
ual differences in DMD severity.
Finally, we have shown that there are distinct changes in EPG
traces in the worm DMD model. The pharynx is a muscular
pump that contracts rhythmically during feeding and can be used
as a model for the vertebrate heart (46). In ∼40% of cases, in
DMD, the cause of death is cardiac failure, so the ability to study
cardiac dysfunction in model organisms is invaluable (71). Our
results raise the possibility of using the worm DMD model to
gain greater mechanistic insight into DMD cardiac pathology, as
well as screening for compounds to ameliorate it.
Conclusion
This work demonstrates the beneficial effect of NaGYY on dys-
1(eg33) health. Using clinically relevant phenotypes, we dem-
onstrated the potential of H2S-releasing compounds in the
treatment of DMD. AP39 alleviated the loss of muscle strength
and ambulation in the C. elegans model, which is due in large
part to improvements in mitochondrial integrity and function.
Control experiments performed by using hydrolyzed compound
(incapable of generating H2S) confirmed that the effects shown
were due to H2S, and not either the parent compound or hy-
drolysis product. The mechanism of action of H2S requires fur-
ther investigation, but we have shown that its mechanism overlaps
with that of prednisone. Given that prednisone and NaGYY do
not provide an enhanced effect when used in combination,
identifying a different class of drugs with a different mechanism
could also be beneficial. Overall, we provide evidence for the use
of H2S compounds, including those which target H2S delivery to
mitochondria, in the treatment of DMD and raise important
questions of the role of H2S in the onset and progression of
DMD pathology.
Materials and Methods
Strains and Culture Conditions. C. elegans strains were cultured at 20 °C on
Petri dishes containing nematode growth medium (NGM) agar and a lawn of
Escherichia coli OP50, unless stated otherwise. Animals for the study were
age-synchronized by gravity synchronization from the L1 stage and allowed
to grow to the desired day of adulthood. The C. elegans strains used in this
study were Bristol strain N2 (WT) and, dys-1(eg33) (strain BZ33), which has a
nonsense mutation in the dys-1 gene; both strains were provided by the
Caenorhabditis Genetics Center. Mitochondrial network integrity was
assessed by using CB5600 [ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I;
him-8(e1489) IV] and CC91 [dys-1(eg33) I; ccIs4251 I; him-8(e1489) IV] (de-
veloped previously in this laboratory).
Pharmacological Compounds. Prednisone (Sigma-Aldrich) was dissolved in
100% ethanol and added directly to NGM after it had been autoclaved and
cooled to 55 °C. The medium was immediately mixed and dispensed to 6-cm
Petri dishes. The final concentration used was 370 μM, unless otherwise
stated. This concentration was selected, as it falls within the range reported
to reduce the number of degenerating cells in the dys-1(cx18);hlh-1(cc561)
model and dys-1(eg33) model (19, 22). NaGYY and its inert hydrolysis
product were synthesized as described by us (32). Commercially sourced
GYY4137 is a morpholine salt (itself biologically active) complexed to un-
disclosed quantities of highly toxic, carcinogenic solvent [dichloromethane;
xCHCl2; at least 1 dichloromethane:2 GYY4137 molecules (32)], which is
metabolized by cells and in vivo to carbon monoxide (72, 73). We therefore
used a pharmaceutically more acceptable sodium salt devoid of these two
confounding factors, in addition to using its established and characterized
hydrolysis product (32), to ensure that our observations were due to slowly
released H2S, and not the parent molecule or hydrolysis product. Com-
pounds were dissolved in double-distilled H2O (ddH2O) before being added
to the surface of a seeded NGM 3-cm Petri dish ∼24 h before use. A thrash
assay was used to determine the optimal dose of 100 μM for NaGYY, and this
dose was used for all studies unless otherwise stated. AP39 was synthesized,
as described by us (34). The compound was dissolved in dimethyl sulfoxide
and diluted in ddH2O before being added to the surface of a seeded NGM
3-cm Petri dish ∼24 h before use. A thrash assay was used to determine the
optimal dose of 100 pM (dose–response curve 1 pM to 100 μM was per-
formed, and 100 pM was the lowest dose to give a beneficial effect), and this
dose was used for all studies.
Thrashing Assay. Thrashing assays were carried out by picking a single adult
animal into 20 μL of M9 buffer on a microscope slide. The number of bends
in 10 s was counted and repeated five times for each worm for three in-
dependent biological replicates. These thrash counts were then multiplied
by six to give the movement rate per minute. One body bend was recorded
as one rightward body bend and leftward body bend. For each treatment,
movement rates for 10 worms were measured with three biologically in-
dependent repeats (35).
NemaFlex Strength Assay. The NemaFlex is a microfluidic device containing an
arena of pillars. The methods used to conduct the NemaFlex strength assay
were as described (22, 36). However, a modified NemaFlex device was used
so that worms could be assessed at an earlier stage of adulthood, as animals
were day 2 adults for these Nemaflex experiments, but up to day 5 in the
previous study (22). The distance from center to center of one pillar to an-
other was 115 μM, and the pillar diameter was ∼44 μM on average; there-
fore, there was ∼71 μM of space that the worm could occupy between
pillars. The pillar height was ∼87 μM. Worms were grown as described
previously to day 2 adults. Briefly, the devices were loaded with one animal
per chamber, and 1-min videos were taken at a rate of ∼5 images per second
on a Zeiss Axio Observer 7 microscope with a 5x objective and a Hamamatsu
OCRA-Flash4.0 digital camera. Movies were then processed by using
in-house-built image-processing software (MATLAB, R2015b), where pillar
deflections were converted to a force value. Approximately 30 worms were
imaged per strain/treatment group.
CeleST Swim Test. CeleST [a specialized computer program that tracks the
swimming behavior of multiple animals in liquid (41)] was used to explore
swimming “gait” in WT, dys-1(eg33), and drug-treated worms. Worms were
grown as described previously to day 1 adults. Methods used were as de-
scribed (74). Briefly, four or five animals were picked into the swimming
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zone (50 μL of M9 buffer into a 10-mm ring preprinted on a microscope
slide), and 30-s movies were taken with ∼15 images per second on a LEICA
MDG41 microscope at 1x magnification with a Leica DFC3000G camera. The
analysis utilized a swim analysis program in MATLAB that read out on sev-
eral parameters associated with aging. Approximately 60 worms were
imaged per strain/treatment group.
Mitochondrial and Cell Death Imaging.Mitochondrial imaging was used in day
1 adults, with or without treatment, to examine the mitochondrial network.
The CB5600 [ccIs4251 (Pmyo-3::Ngfp-lacZ; Pmyo-3::Mtgfp) I; him-8(e1489) IV]
strain and CC91 [dys-1(eg33) I; ccIs4251 I; him-8(e1489) IV] were used for WT
imaging and dystrophy imaging, respectively. Worms were cultured on
NaGYY as described. Approximately 20 day 1 adults were picked into 20 μL
of M9 buffer on a microscope slide with a coverslip applied. Worms were
imaged at 40× magnification using a Nikon Eclipse 50i microscope. CB5600
and CC91 animals were also used for the cell-death images. The protocol
used was as described (20). Briefly animals were assessed at day 4 and day 8
of adulthood, where the number of dead muscle cells was determined by
quantifying the number of muscle cells that had lost their distinct circular
nuclear GFP signal. Approximately 30 animals were picked into 20 μL of M9
buffer on a microscope slide with a coverslip applied. Worms were imaged at
10x magnification by using a Nikon Eclipse 50i microscope.
JC-10. JC-10 (Enzo Life Sciences, catalog no. 52305) was used to assess mi-
tochondrial membrane potential. Worms used for assessing mitochondrial
membrane potential were WT and dys-1(eg33). Approximately 40 day 1
adults were picked into 83 μM JC-10 in freeze-dried OP50 solution (LabTIE)
for 4 h before imaging. Representative images were taken at 40× magnifi-
cation by using a Nikon Eclipse 50i microscope.
Lifespan Assay. Lifespan assays were conducted by using the microfluidics-
based Infinity Screening System (NemaLife Inc.). Worms were grown as de-
scribed to day 0 of adulthood. Day 0 animals were then washed from plates
with 2 mL of M9 and collected in conical tubes. Animals were washed three
times with 14 mL of M9, allowing young adults to settle at the bottom, and
the supernatant was removed to clear bacterial debris. Worms were then
collected in a 2.5-mL sterile syringe, where ∼70 animals were loaded into
each microfluidic chip (Infinity chip, NemaLife Inc.) for whole-life culture
(75). Survival analysis began from day 1 of adulthood and was repeated daily
until cessation of life. Each day, the microfluidic culture chips were washed
to remove progeny and imaged for 90 s, followed by feeding of 20 mg/mL
E. coli OP50 in liquid NGM. Chips were then placed in Petri dishes with damp
tissue wrapped in parafilm and stored at 20 °C until subsequent use. The
acquired videos were scored for live/dead animals by using the Infinity Code
software (NemaLife Inc.).
Development of Animals on RNAi. The RNAi feeding method was adopted in
this study, where worms were fed bacteria expressing double-stranded RNA
(dsRNA) (76). Starved L1s were synchronized onto standard RNAi plates with
bacterial lawns expressing dsRNA for the relevant genes and allowed to
reach day 1 of adulthood before assessment by thrash assay. Clones were
obtained from the Open Biosystems Vidal Library. Clones used were as fol-
lows: jnk-1, B0478.1; skn-1, T19E7.2; and daf-16, R13H8.1. The sir-2.1:
R11A8.4 clone was obtained from the Ahringer library. For each treatment,
movement rates for 10 worms were measured with three biologically
independent repeats.
NemaMetrix ScreenChipTM EPG Recordings. Synchronized worms were grown
to L4 stage as described, with or without treatment. Worms were collected
from the plates with M9 buffer and washed twice with M9 by centrifugation
(2,500 rpm, 90 s). After washing, worms were resuspended in M9 containing
10 mM serotonin (5-hydroxytryptamine) and incubated for 10 min to stim-
ulate pumping. EPG recordings were taken by using the NemaMetrix
ScreenChipTM system using an SC30 chip. Each EPG recording was 2 min in
duration and analyzed by using the NemAquire software. Worms for each
condition were analyzed in two independent experiments and the data
combined, consisting of ∼30 animals. Representative images of the pumps
were extracted from the NemAnalysis 0.2 software.
Antimycin A Assay. Worms were grown to day 1 of adulthood either with or
without treatment as described. One milliliter of M9 buffer containing 2 μM
antimycin A was added to a seeded NGM 3-cm Petri dish. Approximately 30
animals were picked into the buffer and left for 24 h at 20 °C. Individual
animals were picked out of the buffer, and a thrash assay was carried out as
described. For each treatment, movement rates for 10 worms were mea-
sured with three biologically independent repeats.
Rodent Study.
Study approval. Male, C57BL/10ScSn (BL/10), dystrophin-deficient (mdx), and
dystrophin/utrophin-deficient (dko) mice were housed in the Biological Re-
search Facility at The University of Melbourne under a 12-h light/dark cycle
and provided access to drinking water and standard chow ad libitum. All
experiments were approved by the Animal Ethics Committee (AEC 1212507
and 1613961) at The University of Melbourne and conducted in accordance
with the Australian code of practice for the care and use of animals for sci-
entific purposes as stipulated by the National Health and Medical Research
Council (Australia). At the time of death, muscles and organs were excised,
trimmed of nonmuscle tissue, blotted of excess moisture, weighed, and frozen
in liquid nitrogen. Tissues were stored at −80 °C until further analysis.
Immunoblotting. Gastrocnemius samples were powdered on dry ice by using a
Cellcrusher tissue pulverizer (Cellcrusher Ltd.), with 25 mg of muscle ho-
mogenized via shaking in a FastPrep 24 5G (MP Biochemicals) at 6.0 m•s−1 for
80 s in a 10-fold mass of ice-cold sucrose lysis buffer (50 mM Tris, pH 7.5;
270 mM sucrose; 1 mM ethylenediaminetetraacetic acid (EDTA); 1 mM eth-
ylene glycol tetraacetic acid; 1% Triton X-100; 50 mM sodium fluoride; 5 mM
sodium pyrophosphate decahydrate; and 25 mM beta-glycerophosphate).
Inhibitors were added fresh on the day of use and included 1 cOmplete
protease inhibitor cocktail EDTA free tablet (Roche) and Phosphatase In-
hibitor Cocktail 3 (Sigma-Aldrich). Samples were then centrifuged for 10 min
at 8,000 × g at 4 °C to remove any insoluble material. Protein concentrations
were determined by using the DC protein assay as per manufacturer’s in-
structions (Bio-Rad). An equal volume of protein (20 mg) was separated by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis on 12.5% gels at
a constant current of 23 mA per gel for ∼60 min. Proteins were then
transferred onto nitrocellulose membranes (Bio-Rad) by using a wet transfer
system at 100 V for 1 h. Membranes were then stained in Ponceau S
(Sigma-Aldrich) and imaged to check for even loading and transfer. Mem-
branes were then blocked for 1 h in 3% dry milk in Tris-buffered saline with
Tween (TBS-T). Membranes were incubated overnight in primary antibodies
at 4 °C. Following primary antibody incubation, membranes were washed
three times in TBS-T and subsequently incubated in the appropriate horse-
radish peroxidase-conjugated secondary antibody at room temperature for
1 h. Membranes were again washed three times in TBS-T prior to imaging.
Images were captured by using the ChemiDoc (Bio-Rad) and quantified by
using ImageJ.
Antibodies. Polyclonal antibodies to 3-MST (ab85377) and CSE (ab151769)
were from Abcam and used at a concentration of 1:1,000. Anti-rabbit sec-
ondary antibody (7074) was used at a concentration of 1:10,000 in TBS-T and
was from Cell Signaling Technology.
Skeletal muscle sulfide analysis. Total sulfide levels were determined by using
the 7-azido-4-methylcoumarin (AzMC) fluorescent probe approach (Sigma-Aldrich,
catalog no. L511455). Briefly, mouse skeletal muscle was powdered, and
50 mg was lysed using nondenaturing lysis buffer (50 mM Tris·HCl, pH 8.0;
150 mM NaCl; 1% Nonidet P-40; and 1% Triton X-100). The protein con-
centration was determined with DC Protein Assay (Bio-Rad). Tissue lysates
(150 μg of total protein) were loaded into a black, opaque 96-well plate and
combined with AzMC (0.01 mM). The plate was sealed and agitated at
500 rpm/37 °C for 60 min. Fluorescence of AzMC was measured by using a
Clariostar Plus microplate reader (BMG LABTECH) at excitation λ = 365 and
emission λ = 450 nm.
Statistical Analysis. All data are presented as violin plots from at least three
replicates unless otherwise stated. Normality was first assessed by using the
D’Agostino and Pearson tests, and then the statistical test was selected
based on normality. Statistical differences were assessed by using either one-
way ANOVA, two-way ANOVA, or Kruskal–Wallis test. Survival was analyzed
by using Kaplan–Meier curves, with Bonferroni-corrected multiple compar-
isons. Significance was determined as P < 0.05, and all statistical analyses
were completed by using GraphPad Prism.
Data Availability. All study data are included in the article.
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